
NeuroVive´s Clinical Phase II study for traumatic brain injury passes safety evaluation

The Swedish biotechnology company NeuroVive Pharmaceutical recently announced that the ongoing clinical Phase IIa study for traumatic brain injury with the company's drug candidate NeuroSTAT® passed a safety evaluation and is moving on to the higher dosage group with the last 10 of 20 patients. The interim analysis included an evaluation of blood concentrations of cyclosporin A (the active substance in NeuroSTAT®) and changes in intracranial pressure and blood samples collected to analyze possible organ injury.

“We've now obtained important safety data on the lower dose of NeuroSTAT® for treating patients with traumatic brain injury and can now move on to treat patients with the higher dose. This means that the study has reached an important milestone in the clinical trial program of NeuroSTAT®,” commented NeuroVive's CEO Mikael Brönnegård.



More information about the study can be found at: <https://clinicaltrials.gov/ct2/show/NCT01825044>

NeuroVive´s project for the treatment of stroke enters new phase with Isomerase Therapeutics

NeuroVive Pharmaceutical, a Swedish biotechnology company focusing on mitochondrial medicine, is entering a new phase in the company's development project NVP014 for the treatment of ischaemic stroke in collaboration with UK partner Isomerase Therapeutics. The former collaboration with to-BBB of the Netherlands concluded at the end of 2014 and on the basis of the results obtained, NeuroVive is now developing new molecules and a more effective method for penetrating the blood-brain barrier.

The collaboration with Isomerase has already generated new lead compounds that are in pre-clinical evaluation.

“The initiative we've now begun with Isomerase Therapeutics is based on the same chemistry platform as our NVP018/NVP019 compounds, which we view as the next generation cyclophilin inhibitor. We're also developing a new method for improved penetration across the blood-brain barrier,” commented Magnus Hansson, Senior Scientist at NeuroVive.

